Literature DB >> 16629221

Renal osteodystrophy: what's in a name? Presentation of a clinically useful new model to interpret bone histologic findings.

H H Malluche1, M C Monier-Faugere.   

Abstract

Renal osteodystrophy begins early in the course of chronic kidney disease and occurs almost without exception in all patients with Stage 5 disease (CKD-5). Bone biopsies and evaluation of mineralized bone sections after double tetracycline-labeling are currently considered the gold standard for diagnosis and classification of renal osteodystrophy. Nevertheless, bone biopsies are rarely employed. This is, at least in part, related to the paucity of nephrologists trained in performance of the procedure and the fact that reports of the histologic results are not easily translatable to clinical practice. Results are usually given qualitatively, using non-uniform classifications or by histomorphometric evaluations which are esoteric to most nephrologists. We suggest here that histomorphometric evaluation can be reserved for research and special situations. Also, the customarily used qualitative classification should be replaced by a clinically useful nomenclature, provided the interpretation is done by an individual with sufficient experience in bone pathology. We present a new interactive nomenclature for renal osteodystrophy that addresses abnormalities of turnover, abnormalities of bone balance, and abnormalities of mineralization. The new nomenclature, thus, includes disorders of high- and low-turnover with consideration of the interrelation with positive or negative bone balance with or without mineralization defect. In this schema, changes in bone status are described as deviations from a norm, and treatment is geared toward normalizing values rather than creating any absolute change in one direction or another. It is hoped that such a classification will be easily usable, clinically more relevant, and more amenable to individualized treatment guidance.

Entities:  

Mesh:

Year:  2006        PMID: 16629221     DOI: 10.5414/cnp65235

Source DB:  PubMed          Journal:  Clin Nephrol        ISSN: 0301-0430            Impact factor:   0.975


  38 in total

1.  Biomarkers of Bone Turnover Identify Subsets of Chronic Kidney Disease Patients at Higher Risk for Fracture.

Authors:  Jan M Hughes-Austin; Ronit Katz; Richard D Semba; Stephen B Kritchevsky; Douglas C Bauer; Mark J Sarnak; Charles Ginsberg; Michael G Shlipak; Florence Lima; Hartmut H Malluche; Joachim H Ix
Journal:  J Clin Endocrinol Metab       Date:  2020-08-01       Impact factor: 5.958

2.  Lanthanum carbonate stimulates bone formation in a rat model of renal insufficiency with low bone turnover.

Authors:  Toshio Fumoto; Masako Ito; Kyoji Ikeda
Journal:  J Bone Miner Metab       Date:  2013-10-15       Impact factor: 2.626

3.  Intact PTH combined with the PTH ratio for diagnosis of bone turnover in dialysis patients: a diagnostic test study.

Authors:  Johann Herberth; Adam J Branscum; Hanna Mawad; Tom Cantor; Marie-Claude Monier-Faugere; Hartmut H Malluche
Journal:  Am J Kidney Dis       Date:  2010-03-27       Impact factor: 8.860

4.  Bone alkaline phosphatase isoforms in hemodialysis patients with low versus non-low bone turnover: a diagnostic test study.

Authors:  Mathias Haarhaus; Marie-Claude Monier-Faugere; Per Magnusson; Hartmut H Malluche
Journal:  Am J Kidney Dis       Date:  2015-04-02       Impact factor: 8.860

5.  Pediatric solid organ transplantation and osteoporosis: a descriptive study on bone histomorphometric findings.

Authors:  Inari S Tamminen; Helena Valta; Hannu Jalanko; Sari Salminen; Mervi K Mäyränpää; Hanna Isaksson; Heikki Kröger; Outi Mäkitie
Journal:  Pediatr Nephrol       Date:  2014-02-23       Impact factor: 3.714

6.  Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients.

Authors:  Hartmut H Malluche; Hanna W Mawad; Marie-Claude Monier-Faugere
Journal:  J Bone Miner Res       Date:  2011-06       Impact factor: 6.741

7.  Adverse mandibular bone effects associated with kidney disease are only partially corrected with bisphosphonate and/or calcium treatment.

Authors:  Matthew R Allen; Neal X Chen; Vincent H Gattone; Sharon M Moe
Journal:  Am J Nephrol       Date:  2013-11-22       Impact factor: 3.754

8.  Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density.

Authors:  Ben-Chung Cheng; Ying-Chou Chen
Journal:  Clin Rheumatol       Date:  2016-10-18       Impact factor: 2.980

Review 9.  Effects of treatment of renal osteodystrophy on bone histology.

Authors:  Hartmut H Malluche; Hanna Mawad; Marie-Claude Monier-Faugere
Journal:  Clin J Am Soc Nephrol       Date:  2008-11       Impact factor: 8.237

10.  Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients.

Authors:  Carol Moore; Jerry Yee; Hartmut Malluche; D Sudhaker Rao; Marie-Claude Monier-Faugere; Elizabeth Adams; Olufunmilola Daramola-Ogunwuyi; Hassan Fehmi; Saroj Bhat; Yahya Osman-Malik
Journal:  Clin J Am Soc Nephrol       Date:  2009-09       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.